Trials / Completed
CompletedNCT03733392
Advisor HD Grid Observational Study
Advisor High Density (HD) Grid Mapping Catheter Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 379 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to quantify and characterize the outcomes of radiofrequency (RF) ablation after, and the utility of electroanatomical mapping with the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ (hereafter called "HD Grid") and EnSite Precision™ Cardiac Mapping System (SV 2.2 or higher, hereafter called "EnSite Precision") with HD Wave Solution™ voltage mapping (hereafter called "HD Wave Solution") in subjects with persistent atrial fibrillation (PersAF) or ventricular tachycardia (VT) in real-world clinical settings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Advisor HD Grid Mapping Catheter, Sensor Enabled | The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart, i.e., recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart. |
Timeline
- Start date
- 2019-01-11
- Primary completion
- 2021-05-27
- Completion
- 2021-05-27
- First posted
- 2018-11-07
- Last updated
- 2024-04-16
- Results posted
- 2024-04-16
Locations
25 sites across 11 countries: Australia, Austria, Canada, Denmark, France, Germany, Italy, Netherlands, Portugal, South Africa, Spain
Source: ClinicalTrials.gov record NCT03733392. Inclusion in this directory is not an endorsement.